LPPEPTIDE | 5-Amino-1MQ | 10mg x 10 vials | 10 vials / box

What is 10AM?

5-Amino-1MQ is a small molecule investigated as an inhibitor of nicotinamide N-methyltransferase (NNMT), not a peptide. Research in cultured fat cells and diet-induced obese mice measured changes in cellular metabolites and animal obesity measures. NNMT stands for nicotinamide N-methyltransferase. Researchers have investigated this enzyme as a metabolic target, but different kinds of experiments answer different questions.

Research context

5-Amino-1MQ 10 mg dosage information begins with the identity of the material. 5-Amino-1MQ, or 5-amino-1-methylquinolinium, is a small molecule investigated as an NNMT inhibitor, not a peptide. A 10 mg vial states a total mass. Before interpreting that mass, the product documentation must identify the chemical form and the basis of the label claim. A concentration calculation cannot verify the vial’s contents.

What NNMT Inhibition Means

The 2014 NNMT knockdown study reduced the enzyme’s expression in mice. It was not a trial of a commercial 5-Amino-1MQ vial. Later small-molecule research examined NNMT inhibitors in cultured fat cells and diet-induced obese mice. Investigators measured changes in cellular metabolites and animal obesity measures, not outcomes in people using this 5 mg format. This is why the mechanism and the dosage question must remain separate. Evidence that an NNMT inhibitor changes a laboratory endpoint does not determine a human dose, route, frequency, or treatment duration.

LPPeptide handling reference

Amounts and measurements for the 5 mg vial format. Start: 2.5 mg once daily to assess tolerance. Target: 5 mg once daily or 2.5 mg twice daily (BID). Frequency: Once or twice per day (subcutaneous). Vial Duration: Single 5 mg vial lasts 1–2 days at 2.5–5 mg per day. Timing: Morning administration preferred; BID dosing may be split AM/PM.

Storage

5-Amino-1MQ is a small molecule. A generic peptide-storage guide cannot establish its shelf life, solubility, or sterile handling conditions. The exact material needs documented preparation and stability instructions. A mouse experiment that used a saline formulation cannot validate a bacteriostatic-water preparation or a multiweek refrigerated use-by limit for a different product.

Safety observations

The cited 5-Amino-1MQ studies are primarily preclinical. In obese mice, researchers observed changes in body composition when NNMT inhibition was combined with a change in diet. These findings do not establish human benefit or the safety of this preparation. The pharmacokinetic paper measured the compound after intravenous and oral administration in rats. Rat half-life results do not establish the timing of human subcutaneous exposure. Those papers cannot provide a reliable rate of headache, jitteriness, local reactions, or long-term adverse effects in people. Calling the compound generally well tolerated in humans would go beyond the evidence they supply.

Reading Animal Studies Without Overextending Them

Diet was part of the experiment, not background noise. The mouse study compared NNMT inhibition plus a lean-diet substitution with the diet change alone. Its result belongs to that model and comparison. When comparing a paper with a vial, check the species, compound form, route, and diluent before considering the outcome. A mechanism involving NAD+ does not, by itself, justify adding other compounds to a human regimen.